Bengaluru-based semiconductor startup Sophrosyne Technologies has raised $2M in seed round, fully subscribed by Bluehill.VC. The funding will accelerate Sophrosyne’s transition from prototype silicon to full-scale development and global OEM engagement. It will also fuel expansion across silicon design, firmware development, and early customer deployments in India and international markets.

Sophrosyne is building a unified multi-vital biosensing SoC that measures ECG, PPG, respiration, temperature and related signals with exceptional precision at very low energy consumption. By consolidating multiple sensing functions into one compact architecture, the company enables wearable devices to deliver richer and more continuous health insights with a smaller silicon footprint. The company recently cleared technical diligence and was awarded MeitY DLI grant of $1.2M, validating the engineering robustness.

Sridhar Parthasarathi, Managing Partner, Bluehill.VC said, “Wearable health is entering a new phase where accuracy and continuous monitoring are becoming standard expectations. Achieving that requires innovation at the semiconductor level, and Sophrosyne is among the few teams capable of delivering it. Their approach addresses the real constraints device makers face, performance, efficiency, and integration complexity. Bluehill.VC is uniquely positioned to back deep-tech founders building ambitious semiconductor IP from India. We are proud to support Sophrosyne on this journey.”

Talking about the investment, Dr. Manish Srivastava, Co-founder & CEO, Sophrosyne said, “Bluehill.VC’s investment comes at a defining moment for us. We are moving toward production-grade silicon and early OEM rollouts. Having a deep-tech investor like Bluehill.VC, backed by leaders such as Vinod Dham, Manu Iyer & Sridhar Parthasarathi gives us access to world-class semiconductor guidance that few startups can tap into. Beyond capital, Bluehill.VC brings discipline, clarity, and the ability to help us scale this technology globally.”